Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'

Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report. In a May 26 research note, ROTH Capital Partners analyst Tony Butler purported that Atara Biotherapeutics Inc.'s (ATRA:NASDAQ) "updated data from the Phase 1 ...
Streetwise Reports | May 28, 2020 |

Avadel Shares Rise and Shine on Positive Phase 3 Narcolepsy Study Findings

Avadel Pharmaceuticals' shares traded 25% higher reaching a new 52-week high price after the company reported positive topline results from its Pivotal Phase 3 REST-ON trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. ...
Streetwise Reports | April 28, 2020 |

The Euro Bulls Are Back: Targets to Eye

EUR/USD The euro has recently rebounded, and the pair is approaching resistance after swift Friday’s action. Will the bulls be strong enough to overcome it – and if so, where exactly can their efforts take them? These were our Friday&CloseCurlyQuo...
Nadia Simmons | November 18, 2019 |

Aurora Cannabis, EXMceuticals, Tilray - Cannabis development in Portugal

From the street to the clinic. Cannabis had the image of an illegal street drug in most rich countries since the prohibition in the USA in the 1930s. Although cannabis has been used as a medicinal plant for more than 1,000 years, the past decades have been marked by other phar...
Mario Hose | February 4, 2020 |

Buzz on the Bullboards: Rebound, or smoke and mirrors?

Could the recent fears around banking stocks be washing away? Given the recent performance among major indices, it seems possible. Gold held steady as the usual investment haven and that played right into the hands of miners ready with fresh news. Reaping the fr...
Jonathon Brown | March 23, 2023 |

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |

Downside Risk in Gold & Gold Stocks

The big picture fundamentals for precious metals have been trending more bullish in recent months as expectations for the Federal Reserve went from a few rate hikes in 2019 to an expectation of a rate cut within the next 12 months. That is aligned with the peak in the 2-year y...
Jordan Roy-Byrne, CMT | April 16, 2019 |

CoinGecko Publishes 2019 Q1 Cryptoasset Report

April 17, 2019 - CoinGecko has announced the publication of its 2019 Q1 cryptoasset report. The 48-page report gives an overview of the state of the cryptoasset market and the major events that happened in the first quarter of 2019. Total market capitalization of all cr...
CoinGecko | April 16, 2019 |

Buzz on the Bullboards: Buying Binge or Sell-Off Frenzy?

Adrift in a sea of global economic uncertainty and confusion, last week was full of tough questions for investors on the Stockhouse Bullboards. Some of the most popular companies on the website suffered setbacks, while other small caps gained attention as investors looked...
Stockhouse Editorial | February 16, 2022 |

FDA Grants Breakthrough Status to Biopharma's Lead Candidate for Liver Disease

The California firm's most advanced asset is advancing through Phase 2b, according to a ROTH Capital Partners report. In a Feb. 19 research note, analyst Yasmeen Rahimi reported that CymaBay Therapeutics Inc. (CBAY:NASDAQ) is having a strong Q1/19 with respect to cont...
Streetwise Reports | February 26, 2019 |
1 2 3 4 5 6 7 8 9 10 ...